PDCD1 and neoplasm: In the present study, we demonstrated that patients bearing TNBC with high PD-1+ immune infiltrates and high PD-L1 tumor expression were likely to experience significantly improved clinical outcomes, and this was validated both at the transcriptional level as well as through a separate cohort, using publicly accessible data.